{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:15:40Z","timestamp":1786979740594,"version":"build-2736575974"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00198-026-07864-3","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:38:19Z","timestamp":1771328299000},"page":"857-865","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clarifying clinically treatment-naive status for osteoporosis patients"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7679-3965","authenticated-orcid":false,"given":"David L.","family":"Kendler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Habert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raheem B.","family":"Kherani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jooho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Purvis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodie","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubomira","family":"Slatkovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Thain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"7864_CR1","doi-asserted-by":"publisher","first-page":"564","DOI":"10.4158\/GL-2020-0524","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N et al (2020) American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis- 2020 update executive summary. Endocr Pract 26:564\u2013570","journal-title":"Endocr Pract"},{"key":"7864_CR2","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jogc.2021.09.013","volume":"44","author":"AA Khan","year":"2022","unstructured":"Khan AA, Alrob HA, Ali DS, Dandurand K, Wolfman W, Fortier M (2022) Guideline no. 422g: menopause and osteoporosis. J Obstet Gynaecol Can 44:527-536.e525","journal-title":"J Obstet Gynaecol Can"},{"key":"7864_CR3","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","volume":"33","author":"MS LeBoff","year":"2022","unstructured":"LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES (2022) The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 33:2049\u20132102","journal-title":"Osteoporos Int"},{"key":"7864_CR4","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1097\/GME.0000000000001831","volume":"28","author":"North American Menopause Society","year":"2021","unstructured":"North American Menopause Society (2021) Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause 28:973\u2013997","journal-title":"Menopause"},{"key":"7864_CR5","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa048","author":"D Shoback","year":"2020","unstructured":"Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R (2020) Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaa048","journal-title":"J Clin Endocrinol Metab"},{"key":"7864_CR6","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 104:1595\u20131622","journal-title":"J Clin Endocrinol Metab"},{"key":"7864_CR7","doi-asserted-by":"publisher","first-page":"E1333","DOI":"10.1503\/cmaj.221647","volume":"195","author":"SN Morin","year":"2023","unstructured":"Morin SN, Feldman S, Funnell L et al (2023) Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update. Can Med Assoc J 195:E1333-e1348","journal-title":"Can Med Assoc J"},{"key":"7864_CR8","first-page":"1535","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348:1535\u20131541","journal-title":"Fract Interv Trial Res Group Lancet"},{"key":"7864_CR9","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"7864_CR10","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543","journal-title":"N Engl J Med"},{"key":"7864_CR11","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"7864_CR12","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637\u2013645","journal-title":"JAMA"},{"key":"7864_CR13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","volume":"391","author":"DL Kendler","year":"2018","unstructured":"Kendler DL, Marin F, Zerbini CAF et al (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391:230\u2013240","journal-title":"Lancet"},{"key":"7864_CR14","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ et al (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316:722\u2013733","journal-title":"JAMA"},{"key":"7864_CR15","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u20131441","journal-title":"N Engl J Med"},{"key":"7864_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83\u201391","journal-title":"Osteoporos Int"},{"key":"7864_CR17","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427","journal-title":"N Engl J Med"},{"key":"7864_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jbmr.2708","volume":"31","author":"RA Adler","year":"2016","unstructured":"Adler RA, El-Hajj Fuleihan G, Bauer DC et al (2016) Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 31:16\u201335","journal-title":"J Bone Miner Res"},{"key":"7864_CR19","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2021.10815","volume":"22","author":"B Kim","year":"2021","unstructured":"Kim B, Cho YJ, Lim W (2021) Osteoporosis therapies and their mechanisms of action (Review). Exp Ther Med 22:1379","journal-title":"Exp Ther Med"},{"key":"7864_CR20","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1210\/jc.2009-1947","volume":"95","author":"NB Watts","year":"2010","unstructured":"Watts NB, Diab DL (2010) Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95:1555\u20131565","journal-title":"J Clin Endocrinol Metab"},{"key":"7864_CR21","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S0140-6736(21)02646-5","volume":"399","author":"IR Reid","year":"2022","unstructured":"Reid IR, Billington EO (2022) Drug therapy for osteoporosis in older adults. Lancet 399:1080\u20131092","journal-title":"Lancet"},{"key":"7864_CR22","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390:1585\u20131594","journal-title":"Lancet"},{"key":"7864_CR23","unstructured":"Center for Drug Evaluation and Research (2019) NDA\/BLA multi-disciplinary review and evaluation {BLA 761062}. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761062Orig1s000MultidisciplineR.pdf. Accessed 10 Oct 2025"},{"key":"7864_CR24","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1210\/jc.2007-0711","volume":"93","author":"S Boonen","year":"2008","unstructured":"Boonen S, Marin F, Obermayer-Pietsch B et al (2008) Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93:852\u2013860","journal-title":"J Clin Endocrinol Metab"},{"key":"7864_CR25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1359\/jbmr.090716","volume":"25","author":"DL Kendler","year":"2010","unstructured":"Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG (2010) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25:72\u201381","journal-title":"J Bone Miner Res"},{"key":"7864_CR26","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1210\/jc.2016-1801","volume":"101","author":"PD Miller","year":"2016","unstructured":"Miller PD, Pannacciulli N, Brown JP et al (2016) Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab 101:3163\u20133170","journal-title":"J Clin Endocrinol Metab"},{"key":"7864_CR27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","volume":"58","author":"C Roux","year":"2014","unstructured":"Roux C, Hofbauer LC, Ho PR et al (2014) Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone 58:48\u201354","journal-title":"Bone"},{"key":"7864_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/jbmr.4433","volume":"37","author":"R Eastell","year":"2022","unstructured":"Eastell R, Vittinghoff E, Lui LY et al (2022) Validation of the surrogate threshold effect for change in bone mineral density as a surrogate endpoint for fracture outcomes: the FNIH-ASBMR SABRE project. J Bone Miner Res 37:29\u201335","journal-title":"J Bone Miner Res"},{"key":"7864_CR29","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/jbmr.3641","volume":"34","author":"ML Bouxsein","year":"2019","unstructured":"Bouxsein ML, Eastell R, Lui LY, Wu LA, de Papp AE, Grauer A, Marin F, Cauley JA, Bauer DC, Black DM (2019) Change in bone density and reduction in fracture risk: a meta-regression of published trials. J Bone Miner Res 34:632\u2013642","journal-title":"J Bone Miner Res"},{"key":"7864_CR30","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","volume":"39","author":"F Cosman","year":"2024","unstructured":"Cosman F, Lewiecki EM, Eastell R et al (2024) Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024. J Bone Miner Res 39:1393\u20131405","journal-title":"J Bone Miner Res"},{"key":"7864_CR31","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/jbmr.2442","volume":"30","author":"DM Black","year":"2015","unstructured":"Black DM, Reid IR, Cauley JA et al (2015) The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 30:934\u2013944","journal-title":"J Bone Miner Res"},{"key":"7864_CR32","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1210\/jc.2014-1971","volume":"99","author":"F Cosman","year":"2014","unstructured":"Cosman F, Cauley JA, Eastell R, Boonen S, Palermo L, Reid IR, Cummings SR, Black DM (2014) Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? J Clin Endocrinol Metab 99:4546\u20134554","journal-title":"J Clin Endocrinol Metab"},{"key":"7864_CR33","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s00198-019-05002-w","volume":"30","author":"EM Dennison","year":"2019","unstructured":"Dennison EM, Cooper C, Kanis JA, Bruy\u00e8re O, Silverman S, McCloskey E, Abrahamsen B, Prieto-Alhambra D, Ferrari S (2019) Fracture risk following intermission of osteoporosis therapy. Osteoporos Int 30:1733\u20131743","journal-title":"Osteoporos Int"},{"key":"7864_CR34","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/jbmr.11","volume":"25","author":"AV Schwartz","year":"2010","unstructured":"Schwartz AV, Bauer DC, Cummings SR et al (2010) Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 25:976\u2013982","journal-title":"J Bone Miner Res"},{"key":"7864_CR35","doi-asserted-by":"crossref","unstructured":"Canada's Drug Agency (2021) CADTH reimbursement recommendation: romosozumab (Evenity).\u00a0https:\/\/www.cda-amc.ca\/romosozumab. Accessed 10 Oct 2025","DOI":"10.51731\/cjht.2021.210"},{"key":"7864_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11657-022-01106-9","volume":"17","author":"R Goeree","year":"2022","unstructured":"Goeree R, Burke N, Jobin M, Brown JP, Lawrence D, Stollenwerk B, Willems D, Johnson B (2022) Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada. Arch Osteoporos 17:71","journal-title":"Arch Osteoporos"},{"key":"7864_CR37","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1002\/jbmr.4409","volume":"36","author":"JP Brown","year":"2021","unstructured":"Brown JP, Engelke K, Keaveny TM et al (2021) Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial. J Bone Miner Res 36:2139\u20132152","journal-title":"J Bone Miner Res"},{"key":"7864_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116618","volume":"167","author":"A Ganapathy","year":"2023","unstructured":"Ganapathy A, Nieves JW, Keaveny TM, Cosman F (2023) Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis. Bone 167:116618","journal-title":"Bone"},{"key":"7864_CR39","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/jbmr.3384","volume":"33","author":"P Geusens","year":"2018","unstructured":"Geusens P, Marin F, Kendler DL et al (2018) Effects of teriparatide compared with risedronate on the risk of rractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial. J Bone Miner Res 33:783\u2013794","journal-title":"J Bone Miner Res"},{"key":"7864_CR40","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","volume":"19","author":"NB Watts","year":"2008","unstructured":"Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, Grauer A (2008) Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 19:365\u2013372","journal-title":"Osteoporos Int"},{"key":"7864_CR41","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927\u20132938","journal-title":"JAMA"},{"key":"7864_CR42","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jbmr.1494","volume":"27","author":"DM Black","year":"2012","unstructured":"Black DM, Reid IR, Boonen S et al (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27:243\u2013254","journal-title":"J Bone Miner Res"},{"key":"7864_CR43","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1007\/s00198-020-05785-3","volume":"32","author":"K Saag","year":"2021","unstructured":"Saag K, Cosman F, De Villiers T, Langdahl B, Scott BB, Denker AE, Pong A, Santora AC (2021) Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis. Osteoporos Int 32:1879\u20131888","journal-title":"Osteoporos Int"},{"key":"7864_CR44","doi-asserted-by":"publisher","first-page":"335","DOI":"10.7326\/M21-2512","volume":"175","author":"KN Hayes","year":"2022","unstructured":"Hayes KN, Brown KA, Cheung AM, Kim SA, Juurlink DN, Cadarette SM (2022) Comparative fracture risk during osteoporosis drug holidays after long-term risedronate versus alendronate therapy: a propensity score-matched cohort study. Ann Intern Med 175:335\u2013343","journal-title":"Ann Intern Med"},{"key":"7864_CR45","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.clinthera.2019.05.001","volume":"41","author":"P Fardellone","year":"2019","unstructured":"Fardellone P, Lello S, Cano A, de S\u00e1 Moreira E, de Watanabe Oliveira R, Julian GS, Tang B (2019) Real-world adherence and persistence with bisphosphonate therapy in postmenopausal women: a systematic review. Clin Ther 41:1576\u20131588","journal-title":"Clin Ther"},{"key":"7864_CR46","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.4065\/81.8.1013","volume":"81","author":"ES Siris","year":"2006","unstructured":"Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013\u20131022","journal-title":"Mayo Clin Proc"},{"key":"7864_CR47","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/MLR.0000000000001294","volume":"58","author":"JR Curtis","year":"2020","unstructured":"Curtis JR, Saag KG, Arora T, Wright NC, Yun H, Daigle S, Matthews R, Delzell E (2020) Duration of bisphosphonate drug holidays and associated fracture risk. Med Care 58:419\u2013426","journal-title":"Med Care"},{"key":"7864_CR48","first-page":"324","volume":"60","author":"JP Brown","year":"2014","unstructured":"Brown JP, Morin S, Leslie W et al (2014) Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician 60:324\u2013333","journal-title":"Can Fam Physician"},{"key":"7864_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-025-07722-8","author":"G Adami","year":"2025","unstructured":"Adami G, Bartezaghi M, Montanari F et al (2025) Romosozumab early experience in female patients with severe osteoporosis in an Italian real-world setting, the ROMEO study. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-025-07722-8","journal-title":"Osteoporos Int"},{"key":"7864_CR50","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1056\/NEJMoa050336","volume":"353","author":"DM Black","year":"2005","unstructured":"Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ (2005) One year of alendronate after one year of parathyroid hormone (1\u201384) for osteoporosis. N Engl J Med 353:555\u2013565","journal-title":"N Engl J Med"},{"key":"7864_CR51","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972\u2013980","journal-title":"J Clin Endocrinol Metab"},{"key":"7864_CR52","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1007\/s00198-020-05502-0","volume":"31","author":"MR McClung","year":"2020","unstructured":"McClung MR, Bolognese MA, Brown JP, Reginster JY, Langdahl BL, Maddox J, Shi Y, Rojeski M, Meisner PD, Grauer A (2020) A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab. Osteoporos Int 31:2231\u20132241","journal-title":"Osteoporos Int"},{"key":"7864_CR53","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R et al (2018) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res 33:190\u2013198","journal-title":"J Bone Miner Res"},{"key":"7864_CR54","doi-asserted-by":"publisher","unstructured":"Tsourdi E, Zillikens MC, Meier C et al (2020) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaa756","DOI":"10.1210\/clinem\/dgaa756"},{"key":"7864_CR55","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/jbmr.3452","volume":"33","author":"MR McClung","year":"2018","unstructured":"McClung MR, Brown JP, Diez-Perez A et al (2018) Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res 33:1397\u20131406","journal-title":"J Bone Miner Res"},{"key":"7864_CR56","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1007\/s00198-019-05146-9","volume":"30","author":"DL Kendler","year":"2019","unstructured":"Kendler DL, Bone HG, Massari F et al (2019) Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. Osteoporos Int 30:2437\u20132448","journal-title":"Osteoporos Int"},{"key":"7864_CR57","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","volume":"164","author":"R Lindsay","year":"2004","unstructured":"Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, Reginster JY, Stepan JJ, Myers SL, Mitlak BH (2004) Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 164:2024\u20132030","journal-title":"Arch Intern Med"},{"key":"7864_CR58","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/jbmr.536","volume":"27","author":"MR McClung","year":"2012","unstructured":"McClung MR, Boonen S, T\u00f6rring O et al (2012) Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res 27:211\u2013218","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-07864-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-07864-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-07864-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:01:45Z","timestamp":1779292905000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-026-07864-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7864"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-07864-3","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DLK: consultant, advisory board and\/or speaker honoraria from ZP Pharma, Amgen and Sandoz. JH: consultant, advisory board member and\/or speaker for Boehringer, Eli-Lilly, Elvium, Bausch, AstraZeneca, Novartis, Lundbeck, Novo-Nordisk, Janssen, Eisai, HLS, Otsuka, Idorsia Pfizer, Amgen, Abbvie, GSK, and Bayer. AAK: honoraria from Amgen and research grants from Ascendis, AstraZeneca, Bidgebio, and Takeda. SK: no financial disclosures with commercial or industry entities; serves on the Scientific Advisory Council for Osteoporosis Canada as a volunteer member. CSK: advisory board honoraria from Amgen, Ipsen, Kyowa Kirin, and Pendopharm. JL: advisory board and speaker honoraria, and research grants from Amgen. JP: no financial disclosures with commercial or industry entities. JR: advisory board and\/or speaker honoraria from Amgen. LS: consultant for Amgen. JT: advisory board and\/or speaker honoraria from Amgen and Kyowa Kirin; research grants from Amgen; and employed as the Clinical Lead for Hip Fracture by Ontario Health. JDA: advisory board and\/or speaker honoraria from Alexion, Amgen, Organon, and Sandoz; research grants from Canadian Institutes of Health Research; and advisor for Osteoporosis Canada.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}